Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

ClinicalTrials.gov ID: NCT04026412

Public ClinicalTrials.gov record NCT04026412. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).

Study identification

NCT ID
NCT04026412
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
925 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 7, 2019
Primary completion
Mar 21, 2024
Completion
Nov 25, 2024
Last update posted
Jul 23, 2025

2019 – 2024

United States locations

U.S. sites
24
U.S. states
11
U.S. cities
19
Facility City State ZIP Site status
Local Institution - 0119 La Jolla California 92093
Local Institution - 0207 San Francisco California 94115
Local Institution - 0166 San Francisco California 94143
Local Institution - 0129 Lone Tree Colorado 80124
Local Institution - 0233 Jacksonville Florida 32207
Local Institution - 0219 Orlando Florida 32804
Local Institution - 0039 Pensacola Florida 32504
Local Institution - 0125 Atlanta Georgia 30322
Local Institution - 0165 Augusta Georgia 30912
Local Institution - 0218 Edgewood Kentucky 41017
Local Institution - 0108 Bethesda Maryland 20817
Local Institution - 0116 Traverse City Michigan 49684
Local Institution - 0053 Cincinnati Ohio 45220
Local Institution - 0131 Cincinnati Ohio 45242
Local Institution - 0188 Cincinnati Ohio 45267
Local Institution - 0112 Cleveland Ohio 44106
Local Institution - 0124 Cleveland Ohio 44106
Local Institution - 0047 Cleveland Ohio 44109
Local Institution - 0123 Youngstown Ohio 44501
Local Institution - 0077 Charleston South Carolina 29414
Local Institution - 0191 Austin Texas 78731
Local Institution - 0079 Bryan Texas 77802
Local Institution - 0130 Dallas Texas 75203
Local Institution - 0071 Burlington Vermont 05405

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 159 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04026412, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 23, 2025 · Synced Sep 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04026412 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →